Non-Small Cell Lung Cancer - Oncology Matrix

Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non-small Cell Lung Cancer: Update From the COAST Randomized Clinical Trial

Research Summary: Durvalumab after concurrent chemoradiotherapy (cCRT) is standard-of-care for patients with unresectable, Stage III non-small cell lung cancer (NSCLC) without progression. The COAST study evaluated whether adding novel immunotherapies targeting cluster of differentiation 73 (CD73; oleclumab) or natural killer Group 2 member A (NKG2A;...

ESMO Congress 2025 Meeting Highlights: Non-Small Cell Lung Cancer

Osimertinib then chemotherapy in EGFR-mutated lung cancer with osimertinib third-line rechallenge (OCELOT-cohort A interim analysis). This ongoing multicenter Phase II trial is evaluating third-line (3L) osimertinib rechallenge in patients with epidermal growth factor receptor mutation–positive (EGFR+) advanced non-small cell lung cancer (NSCLC) after first-line osimertinib...

Journal Watch: Hot Topics in Non-small Cell Lung Cancer December 2025

Real-world outcomes and subsequent treatment patterns in patients with advanced non-small cell lung cancer and atypical EGFR mutations receiving first-line osimertinib monotherapy Nieva JJ, Wang X, Doroshow D, et al. Oncol Ther. 2025. Epub ahead of print. Summary. Researchers assessed outcomes of first-line osimertinib monotherapy...

Neoadjuvant Osimertinib for Resectable EGFR-mutated Non-small Cell Lung Cancer

Research Summary In this randomized, controlled, Phase III study,1 patients with resectable, epidermal growth factor receptor (EGFR)–mutated, Stage II to IIIB non-small cell lung cancer (NSCLC) were assigned 1:1:1 to receive neoadjuvant osimertinib (80mg orally once daily for at least nine weeks) plus platinum-based chemotherapy...

Equalizing Prognostic Disparities in Patients with KRAS-mutated Stage III NSCLC: Addition of Durvalumab to Combined Chemoradiotherapy Improves Survival

Research Summary Concurrent chemoradiotherapy (cCRT) followed by adjuvant durvalumab is the standard first-line treatment for patients with unresectable Stage III non-small cell lung cancer (NSCLC) and programmed death-ligand 1 (PD-L1) expression of one percent or higher. Although KRAS mutations are common in NSCLC, their prognostic...

Osimertinib for Patients with EGFR-mutant NSCLC with Acquired T790M and EGFR Amplification After First-generation EGFR-TKI Resistance

Research Summary For patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), EGFR-tyrosine kinase inhibitors (TKIs) can be used as first-line treatment. However, treatment resistance often occurs with first- or second-generation EGFR-TKI treatment, with T790M mutation being the most common acquired resistance...

Durvalumab After Chemoradiotherapy for Locoregional Recurrence of Completely Resected Non-small Cell Lung Cancer (NEJ056)

Research Summary Up to 35 percent of patients with completely resected non-small cell lung cancer (NSCLC) experience locoregional recurrence (LR), and many of these patients cannot undergo further surgery. Other treatment methods are thus necessary for this patient population. Patients with LR following complete resection...

Digital Editions